Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972403 | 0.89 | PLA2G2A (0.45) | PLA2G2APLA2G4A | |
| SCHEMBL17976777 | 0.88 | S1PR1 (0.40) | PLA2G4AENPP2LPAR1LPAR3LPAR6 | |
| SCHEMBL17174997 | 0.83 | DAGLA (0.37) | PLA2G2A | |
| SCHEMBL17174995 | 0.81 | CNR1 (0.36) | PLA2G2A | |
| SCHEMBL17976780 | 0.78 | PLA2G2A (0.35) | PLA2G2APLA2G4AS1PR2S1PR1S1PR3 | |
| SCHEMBL17972402 | 0.75 | CTSK (0.39) | SMN1; SMN2 | |
| SCHEMBL15948704 | 0.74 | EPHX1 (0.35) | PLA2G2A | |
| SCHEMBL16367514 | 0.72 | PLA2G4A (0.34) | PLA2G4A | |
| SCHEMBL19101045 | 0.72 | PLA2G4A (0.34) | PLA2G4A | |
| SCHEMBL31303197 | 0.71 | MEN1 (0.44) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PLA2G2A 1701/4885PLA2G4A 1260/4885ENPP2 349/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | PLA2G2A 2169/4885PLA2G4A 1829/4885ENPP2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.